Market Research Hub

Report takes the reader through a comprehensive review Cancer Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Diagnostics partnering deals.

Albany, NY -- (SBWIRE) -- 05/22/2017 -- Cancer Diagnostics have become fully rooted in modern cancer treatment programs and will continue to have an expanding role. Market Research Hub (MRH) has recently added a new research study to its online repository, titled as "Global Cancer Diagnostic Partnering 2010-2016: Deal trends, players, financials, and forecasts". This 700-pages report provides comprehensive analysis and access to cancer diagnostic partnering deals and agreements managed by the world's foremost healthcare companies. Additionally, the report presents financial deal term values for Cancer diagnostics deals, catalog by headline value, upfront payments, milestone payments and royalties, facilitating readers to analyze and target the financial value of deals.

In the introductory part, the report describes the cancer diagnostic partnering over the years along with most active dealmakers and deal terms. In addition to this, cancer diagnostics partnering by deal type and by therapy area are discussed. Cancer is a deadly disease that affects millions of people all over the world. The incidence of cancer is expecting to rise a further 57 % in the next two decades. Earlier and more accurate detection combined with better monitoring of cancer or pre-cancer conditions is increasing the patients chance to survive this serious health condition. Many researchers believe that the best way to treat cancer is using a multidimensional approach.

The partnership aims to build deep learning applications in computational pathology, enabling this form of artificial intelligence to be applied to massive pathology data sets to better inform diagnostic and treatment decisions. Considering this fact, there are several leading healthcare companies are active for the better diagnostic of various types of cancer. The technological advances of the past decade have helped researchers to characterize the molecular basis of cancer. With this knowledge, drugs targeted at specific molecules have been designed.

The middle section of the report highlights the primary dealmakers in the Cancer Diagnostics partnering field, followed by a comprehensive listing of Cancer Diagnostics deals signed and announced by that company, as well as contract documents since Jan 2010. The deal trends and partnering will bring the unique opportunity to network with colleagues from different sectors and discuss new research in cancer diagnostics. This forecast study provides comprehensive access to available deals and contract documents for over 1,200 Cancer Diagnostics deals.

One of the key highpoints of the study is that over 1,200 online deal records of actual Cancer Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format by company A-Z, stage of development, deal type, therapy focus, and technology type - which is easy to reference. Every deal record in the report links via Weblink to an online version of the deal.

Moreover, the report also includes numerous tables and figures that illustrate the trends and activities in antibody partnering and deal making since 2010 to 2017.

About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH's expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.